Revolution Health

Revolution Medicines is a clinical-stage precision oncology company dedicated to developing innovative, targeted therapies for RAS-addicted cancers. The company leverages its proprietary tri-complex inhibitor platform to discover and develop small molecules that target the active (ON) state of RAS proteins, addressing a major class of oncogenic drivers previously considered undruggable. Its lead candidate, daraxonrasib (RMC-6236), is a first-in-class RAS(ON) multi-selective inhibitor currently in Phase 3 development for pancreatic ductal adenocarcinoma and non-small cell lung cancer. The company's deep pipeline also includes allele-specific inhibitors targeting KRAS G12C, G12D, and G12V mutations, as well as inhibitors of the RAS signaling pathway such as SHP2. Through its "RAS(ON) inhibitor" strategy, Revolution Medicines aims to provide comprehensive treatment options for the approximately 30% of all human cancers driven by RAS mutations.